DMK
CRSP icon

David M. Knott’s CRISPR Therapeutics CRSP Stock Holding History

David M. Knott’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$224K Hold
2,000
– – 0.08% 94
2021
Q2 		$324K Buy
+2,000
New +$243K 0.12% 88

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

David M. Knott's CRSP Position: Q3 2021 in Review

David M. Knott held its CRISPR Therapeutics (CRSP) position steady in Q3 2021 at 2,000 shares worth $224K. The position accounts for 0.08% of the portfolio, ranked #94.

David M. Knott first reported a position in CRSP in Q2 2021 and has held it in 2 quarters since. The position peaked at $324K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • David M. Knott held 2,000 shares of CRISPR Therapeutics worth $224K as of Q3 2021.
  • David M. Knott left its CRISPR Therapeutics share count unchanged in Q3 2021.
  • CRISPR Therapeutics made up 0.08% of David M. Knott's portfolio in Q3 2021, its #94 holding.
  • David M. Knott first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • David M. Knott's CRISPR Therapeutics position peaked at $324K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.